These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 1579785)

  • 1. RP 62203, a 5-hydroxytryptamine2 antagonist, enhances deep NREM sleep in rats.
    Stutzmann JM; Eon B; Lucas M; Blanchard JC; Laduron PM
    Sleep; 1992 Apr; 15(2):119-24. PubMed ID: 1579785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 5-HT2 antagonist ritanserin decreases sleep in cats.
    Sommerfelt L; Ursin R
    Sleep; 1993 Jan; 16(1):15-22. PubMed ID: 8456229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological characterization of RP 62203, a novel 5-hydroxytryptamine 5-HT2 receptor antagonist.
    Doble A; Girdlestone D; Piot O; Allam D; Betschart J; Boireau A; Dupuy A; Guérémy C; Ménager J; Zundel JL
    Br J Pharmacol; 1992 Jan; 105(1):27-36. PubMed ID: 1596688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of zimeldine, a selective 5-HT reuptake inhibitor, combined with ritanserin, a selective 5-HT2 antagonist, on waking and sleep stages in rats.
    Bjorvatn B; Ursin R
    Behav Brain Res; 1990 Nov; 40(3):239-46. PubMed ID: 2149499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of the 5-HT2 antagonist ritanserin on sleep-walking cycle in the rat.
    Silhol S; Glin L; Gottesmann C
    Pharmacol Biochem Behav; 1992 Jan; 41(1):241-3. PubMed ID: 1539075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel 5-HT2 receptor antagonist, RP 62203, selectively blocks serotoninergic but not dopaminergic-induced inhibition in the rat prefrontal cortex.
    Godbout R; Mantz J; Glowinski J; Thierry AM
    Eur J Pharmacol; 1991 Oct; 204(1):97-100. PubMed ID: 1666564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ritanserin, a serotonin-2 receptor antagonist, improves ultradian sleep rhythmicity in young poor sleepers.
    Viola AU; Brandenberger G; Toussaint M; Bouhours P; Paul Macher J; Luthringer R
    Clin Neurophysiol; 2002 Mar; 113(3):429-34. PubMed ID: 11897543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are 5-HT2 antagonists endowed with anxiolytic properties in rodents?
    Stutzmann JM; Eon B; Darche F; Lucas M; Rataud J; Piot O; Blanchard JC; Laduron PM
    Neurosci Lett; 1991 Jul; 128(1):4-8. PubMed ID: 1681477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-dependent effects of the 5-HT1A receptor agonist 8-OH-DPAT on sleep and wakefulness in the rat.
    Monti JM; Jantos H
    J Sleep Res; 1992 Sep; 1(3):169-175. PubMed ID: 10607047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sleep and 5-HT2 receptor sensitivity in recovered depressed patients.
    da Roza Davis JM; Sharpley AL; Solomon RA; Cowen PJ
    J Affect Disord; 1992 Mar; 24(3):177-81. PubMed ID: 1573126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonin control of sleep-wake behavior.
    Monti JM
    Sleep Med Rev; 2011 Aug; 15(4):269-81. PubMed ID: 21459634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 5-HT1A agonist ipsapirone enhances EEG slow wave activity in human sleep and produces a power spectrum similar to 5-HT2 blockade.
    Seifritz E; Moore P; Trachsel L; Bhatti T; Stahl SM; Gillin JC
    Neurosci Lett; 1996 May; 209(1):41-4. PubMed ID: 8734905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [3H]RP 62203, a ligand of choice to label in vivo brain 5-HT2 receptors.
    Fajolles C; Boireau A; Ponchant M; Laduron PM
    Eur J Pharmacol; 1992 May; 216(1):53-7. PubMed ID: 1526254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endogenous excitatory drive modulating respiratory muscle activity across sleep-wake states.
    Chan E; Steenland HW; Liu H; Horner RL
    Am J Respir Crit Care Med; 2006 Dec; 174(11):1264-73. PubMed ID: 16931636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavioral sleep-wake homeostasis and EEG delta power are decoupled by chronic sleep restriction in the rat.
    Stephenson R; Caron AM; Famina S
    Sleep; 2015 May; 38(5):685-97. PubMed ID: 25669184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoradiographic studies of RP 62203, a potent 5-HT2 receptor antagonist. In vitro and ex vivo selectivity profile.
    Malgouris C; Flamand F; Doble A
    Eur J Pharmacol; 1993 Mar; 233(1):29-35. PubMed ID: 8386088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ritanserin-induced changes in sleep-waking phases in rats.
    Kirov R; Moyanova S
    Acta Physiol Pharmacol Bulg; 1995; 21(4):87-92. PubMed ID: 8830880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of pharmacologic treatments on the sleep of depressed patients.
    Sharpley AL; Cowen PJ
    Biol Psychiatry; 1995 Jan; 37(2):85-98. PubMed ID: 7718684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melatonin modulates the sensitivity of 5-hydroxytryptamine-2 receptor-mediated sleep-wakefulness regulation in the rat.
    Dugovic C; Leysen JE; Wauquier A
    Neurosci Lett; 1989 Oct; 104(3):320-5. PubMed ID: 2510097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sleep and EEG power spectrum effects of the 5-HT1A antagonist NAN-190 alone and in combination with citalopram.
    Neckelmann D; Bjørkum AA; Bjorvatn B; Ursin R
    Behav Brain Res; 1996 Feb; 75(1-2):159-68. PubMed ID: 8800653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.